PER Oncology Town Hall™ 2025 ESMO-GI Congress Highlights: The Latest Data on Immune-Based Strategies Across Hepatobiliary Cancers

Details

Targeted and immunologic approaches have fundamentally changed the treatment landscape for patients with advanced hepatobiliary cancers. As new treatment approaches are introduced as options in this setting, keeping pace with updates to pivotal trials is of critical importance. In this program, expert faculty in the management of hepatocellular and biliary tract cancers describe key recent clinical trial findings relating to delivery of therapy, coordination of care, and optimal patient selection along the treatment continuum.

Topics Covered

Gastrointestinal Cancer

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate immune-based treatment strategies for advanced hepatobiliary cancers and their applicability to diverse patient populations, including those with hepatic dysfunction or poor performance status.
• Apply recent evidence to inform treatment selection, sequencing, and delivery of immunotherapy in hepatocellular and biliary tract cancers across frontline and emerging therapeutic settings.

Target Audience

This educational activity is directed toward US-based medical oncologists, gastrointestinal oncologists, advanced practice providers, nurses, and other health care providers who treat patients with gastrointestinal cancers.

Additional credit info

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.